PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22889300-8	2012	Virological studies showed that the combination of R284K with TAM1 mutations confers a fitness advantage in the presence of zidovudine or tenofovir.	Tenofovir	138-147	stromal interaction molecule 1	Homo sapiens	62-66	
22889300-12	2012	CONCLUSIONS: Our study shows the association of R284K and TAM1 mutations in individuals failing therapy with tenofovir/emtricitabine, and unveils a novel mechanism by which secondary mutations are selected in the context of drug-resistance mutations.	Tenofovir	109-118	stromal interaction molecule 1	Homo sapiens	58-62